Sean Lavin
Stock Analyst at BTIG
(3.06)
# 1,113
Out of 5,182 analysts
42
Total ratings
80%
Success rate
33.17%
Average return
Main Sectors:
Stocks Rated by Sean Lavin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TCMD Tactile Systems Technology | Downgrades: Neutral | n/a | $24.60 | - | 4 | Nov 5, 2024 | |
| HOLX Hologic | Downgrades: Neutral | n/a | $75.65 | - | 5 | Jul 18, 2022 | |
| PODD Insulet | Upgrades: Buy | $320 | $204.31 | +56.62% | 5 | Feb 3, 2022 | |
| MDT Medtronic | Downgrades: Neutral | n/a | $86.63 | - | 1 | Jan 10, 2022 | |
| ATRC AtriCure | Maintains: Buy | $42 → $48 | $29.07 | +65.12% | 3 | Feb 19, 2020 | |
| MASI Masimo | Downgrades: Neutral | n/a | $178.55 | - | 4 | Apr 16, 2019 | |
| HSDT Solana Company | Downgrades: Neutral | n/a | $1.86 | - | 4 | Apr 16, 2019 | |
| IRTC iRhythm Holdings | Upgrades: Buy | $80 | $116.80 | -31.51% | 3 | Apr 3, 2019 | |
| NEO NeoGenomics | Upgrades: Outperform | n/a | $8.00 | - | 4 | Apr 16, 2018 | |
| ABT Abbott Laboratories | Downgrades: Neutral | n/a | $102.87 | - | 1 | Jan 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $62.82 | - | 1 | Nov 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $62.22 | - | 3 | May 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $81.05 | - | 4 | Feb 2, 2017 |
Tactile Systems Technology
Nov 5, 2024
Downgrades: Neutral
Price Target: n/a
Current: $24.60
Upside: -
Hologic
Jul 18, 2022
Downgrades: Neutral
Price Target: n/a
Current: $75.65
Upside: -
Insulet
Feb 3, 2022
Upgrades: Buy
Price Target: $320
Current: $204.31
Upside: +56.62%
Medtronic
Jan 10, 2022
Downgrades: Neutral
Price Target: n/a
Current: $86.63
Upside: -
AtriCure
Feb 19, 2020
Maintains: Buy
Price Target: $42 → $48
Current: $29.07
Upside: +65.12%
Masimo
Apr 16, 2019
Downgrades: Neutral
Price Target: n/a
Current: $178.55
Upside: -
Solana Company
Apr 16, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.86
Upside: -
iRhythm Holdings
Apr 3, 2019
Upgrades: Buy
Price Target: $80
Current: $116.80
Upside: -31.51%
NeoGenomics
Apr 16, 2018
Upgrades: Outperform
Price Target: n/a
Current: $8.00
Upside: -
Abbott Laboratories
Jan 22, 2018
Downgrades: Neutral
Price Target: n/a
Current: $102.87
Upside: -
Nov 30, 2017
Upgrades: Buy
Price Target: n/a
Current: $62.82
Upside: -
May 3, 2017
Downgrades: Neutral
Price Target: n/a
Current: $62.22
Upside: -
Feb 2, 2017
Downgrades: Neutral
Price Target: n/a
Current: $81.05
Upside: -